Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.74 |
| ▸ | MEN1 | O00255 | 10/20 | 0.74 |
| ▸ | KDM4A | O75164 | 1/20 | 0.74 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.74 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12857769 | 0.86 | KMT2A (0.73) | KMT2AMEN1KDM4ACTDSP1KDM4C | |
| SCHEMBL10888080 | 0.83 | PLG (0.66) | KMT2AMEN1GAANPC1ABCG2 | |
| SCHEMBL12857674 | 0.81 | KMT2A (0.73) | KMT2AMEN1KDM4ACTDSP1KDM4C | |
| SCHEMBL12857694 | 0.80 | MEN1 (0.80) | KMT2AMEN1POLBGAANPC1 | |
| SCHEMBL16562242 | 0.79 | EGLN1 (0.69) | KMT2AMEN1CTDSP1MAPTLMNA | |
| SCHEMBL6206373 | 0.78 | PSEN1 (0.60) | KMT2AMEN1POLBGAANPC1 | |
| SCHEMBL11326714 | 0.77 | MEN1 (0.78) | KMT2AMEN1GAANPC1MAPT | |
| SCHEMBL4927732 | 0.76 | GAA (0.75) | KMT2AMEN1CTDSP1POLBGAA | |
| SCHEMBL11705060 | 0.76 | MAPT (0.79) | KMT2AGAANPC1MAPTLMNA | |
| SCHEMBL11319471 | 0.76 | NPC1 (0.62) | KMT2AMEN1NPC1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | KMT2A 3993/4885MEN1 2560/4885KDM4A 4342/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | KMT2A 3993/4885MEN1 2560/4885KDM4A 4342/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | KMT2A 3993/4885MEN1 2560/4885KDM4A 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.